Todd Zeno, DPM
Podiatrist · Hanover, PANPI 1124089255
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,585 of the $2,514 with a category attached, or 63.1%. Stryker accounts for 76.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $1,822 and has fallen 80.1% since, to $363 in 2025.
Across 35 payments — averaging $71.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$2K
- Treace Medical Concepts, Inc.$259
- Smith+Nephew$65
- Trice Medical, Inc.$51
- Paratek Pharmaceuticals, Inc.$46
- Averitas Pharma Inc.$34
- plus $143 from 6 others
What the payments were for
- Travel & lodging$1,58563%
- Food & beverage$92937%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 14 | $1,914 |
| Treace Medical Concepts, Inc. | 6 | $259 |
| Smith+Nephew | 4 | $65 |
| Trice Medical, Inc. | 1 | $51 |
| Paratek Pharmaceuticals, Inc. | 3 | $46 |
| Averitas Pharma Inc. | 1 | $34 |
| Kerecis Limited | 1 | $33 |
| Solventum Corporation | 1 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
| Omeros Corporation | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRIME SERIES$1,585
- BIOFOAM$108
- TMC SPEEDMTP$102
How this compares
$2,514 in reported general payments places this provider in the 75th percentile of 445 podiatrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 26 | $1,001 |
| Gabapentin | 35 | $437 |
| Ketoconazole | 16 | $222 |
| Methylprednisolone | 37 | $211 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $190 |
| Triamcinolone Acetonide | 34 | $188 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $135 |
| Clindamycin Hcl | 11 | $76 |
| Cephalexin | 13 | $69 |
| Prednisone | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Hanover
- Mark HofbauerBelle Vernon$1.1M
- Daniel PerezPhiladelphia$434K
- Christopher BarrettChester$229K
- Alan CatanzaritiPittsburgh$80K
- John StarinskiPen Argyl$74K
- Kwasi KwaaduPhiladelphia$65K
- Luke CicchinelliPhiladelphia$62K
- James McGuirePhiladelphia$60K
- John SchelandClarks Summit$54K
- John LapelusaYork$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.